Artificial Intelligence Regulation
Article
Regulatory & Compliance
Last updated: Nov 7, 2025
Every drug sponsor wants to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. That’s always something of a moving target, especially in a field as new as AI. The Pink Sheet’s globe-spanning coverage has produced one rule of thumb, however: The closer AI is to patient care, the more scrutiny it will get. Regulators seem content to allow firms to make product development decisions based on AI without significant oversight.
Download a sample of our coverage from Asia, Europe, and the United States of the emerging framework for artificial intelligence regulation.
OCT 30, 2024
Article
Regulatory & Compliance
EU’s Pharma Legislative Reform
Every drug sponsor wants to make the best use of Artificial Intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from Asia, Europe and the United States of the emerging framework for AI regulation.
